keyword
MENU ▼
Read by QxMD icon Read
search

Breast endocrine surgery

keyword
https://www.readbyqxmd.com/read/27908454/fulvestrant-500-mg-versus-anastrozole-1-mg-for-hormone-receptor-positive-advanced-breast-cancer-falcon-an-international-randomised-double-blind-phase-3-trial
#1
John F R Robertson, Igor M Bondarenko, Ekaterina Trishkina, Mikhail Dvorkin, Lawrence Panasci, Alexey Manikhas, Yaroslav Shparyk, Servando Cardona-Huerta, Kwok-Leung Cheung, Manuel Jesus Philco-Salas, Manuel Ruiz-Borrego, Zhimin Shao, Shinzaburo Noguchi, Jacqui Rowbottom, Mary Stuart, Lynda M Grinsted, Mehdi Fazal, Matthew J Ellis
BACKGROUND: Aromatase inhibitors are a standard of care for hormone receptor-positive locally advanced or metastatic breast cancer. We investigated whether the selective oestrogen receptor degrader fulvestrant could improve progression-free survival compared with anastrozole in postmenopausal patients who had not received previous endocrine therapy. METHODS: In this phase 3, randomised, double-blind trial, we recruited eligible patients with histologically confirmed oestrogen receptor-positive or progesterone receptor-positive, or both, locally advanced or metastatic breast cancer from 113 academic hospitals and community centres in 20 countries...
November 28, 2016: Lancet
https://www.readbyqxmd.com/read/27893470/the-association-between-out-of-pocket-costs-and-adherence-to-adjuvant-endocrine-therapy-among-newly-diagnosed-breast-cancer-patients
#2
Albert J Farias, Ryan N Hansen, Steven B Zeliadt, India J Ornelas, Christopher I Li, Beti Thompson
OBJECTIVE: To determine how out-of-pocket costs for adjuvant endocrine therapy (AET) medication affects adherence among newly diagnosed breast cancer survivors with private health insurance who initiate therapy. MATERIALS AND METHODS: We examined medical and pharmacy claims for the 1-year period after initiating AET using the Truven Health Analytics MarketScan database. Adherence was defined as ≥80% proportion of days covered. Mean out-of-pocket costs for AET fill were measured as the sum of copayments, coinsurance, and deductibles and adjusted to 30-day amounts...
November 23, 2016: American Journal of Clinical Oncology
https://www.readbyqxmd.com/read/27865536/breast-cancer
#3
REVIEW
Nadia Harbeck, Michael Gnant
Breast cancer is one of the three most common cancers worldwide. Early breast cancer is considered potentially curable. Therapy has progressed substantially over the past years with a reduction in therapy intensity, both for locoregional and systemic therapy; avoiding overtreatment but also undertreatment has become a major focus. Therapy concepts follow a curative intent and need to be decided in a multidisciplinary setting, taking molecular subtype and locoregional tumour load into account. Primary conventional surgery is not the optimal choice for all patients any more...
November 16, 2016: Lancet
https://www.readbyqxmd.com/read/27856201/daily-practice-management-of-pt1a-b-pn0-breast-carcinoma-a-prospective-french-odissee-cohort-study
#4
Florence Dalenc, Frédérique Penault-Llorca, Monique Cohen, Gilles Houvenaeghel, Jean-Marc Piat, Philippe Liegeois, Laurent Puyuelo, Jean-Philippe Suchaud, Mohammed Zouai, Magali Lacroix-Triki, Nina Radosevic-Robin, Chahinez Benkanoun, Hanane Attar-Rabia, Marie-Pierre Chauvet, Joseph Gligorov, Yazid Belkacemi
BACKGROUND: Most breast cancer (BC) tumors ≤10 mm have an excellent prognosis. The subgroups with a higher risk for distant recurrence requiring adjuvant systemic therapy are not precisely defined in current international guidelines. PATIENTS AND METHODS: The OBSERVATOIRE DES PETITS CANCERS DU SEIN HER2 +/- (ODISSEE) study was a prospective, multicenter, cohort study that aimed to describe the daily adjuvant management and outcome of 616 patients with unifocal, invasive pT1a-b pN0 nonmetastatic BC who underwent surgery...
August 31, 2016: Clinical Breast Cancer
https://www.readbyqxmd.com/read/27846443/hr-her2-breast-cancer-in-pre-menopausal-women-the-impact-of-younger-age-on-clinical-characteristics-at-diagnosis-disease-management-and-survival
#5
Marianna De Camargo Cancela, Harry Comber, Linda Sharp
Young women (20-39 years-old) with breast cancer are diagnosed with more aggressive tumours and consequently have poorer survival. However, there is an evidence gap as to whether age has an independent effect on survival of pre-menopausal women diagnosed with HR+/Her2- tumours. The aim of this population-based study was to compare characteristics at diagnosis, determinants of treatment and survival in women aged 20-39 and 40-49 years diagnosed with HR+/Her2- tumours. From the National Cancer Registry Ireland, we identified women aged 20-49 diagnosed with a first invasive HR+/Her2- breast cancer during 2002-2008...
December 2016: Cancer Epidemiology
https://www.readbyqxmd.com/read/27771840/comparing-treatment-and-outcomes-of-ductal-carcinoma-in-situ-among-women-in-missouri-by-race
#6
Chinwe C Madubata, Ying Liu, Melody S Goodman, Shumei Yun, Jennifer Yu, Min Lian, Graham A Colditz
PURPOSE: To investigate whether treatment (surgery, radiation therapy, and endocrine therapy) contributes to racial disparities in outcomes of ductal carcinoma in situ (DCIS). PATIENTS AND METHODS: The analysis included 8184 non-Hispanic White and 954 non-Hispanic Black women diagnosed with DCIS between 1996 and 2011 and identified in the Missouri Cancer Registry. Logistic regression models were used to estimate odds ratios (ORs) of treatment for race. We used Cox proportional hazards regression models to estimate hazard ratios (HRs) of ipsilateral breast tumor (IBT) and contralateral breast tumor (CBT) for race...
October 22, 2016: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/27770672/population-based-analysis-of-breast-cancer-treatment-by-intrinsic-sub-type-in-manitoba-canada
#7
Elizabeth Hammond, Emma Shu, Karagin Sawchuk, Yvonne Myal, Afshin Raouf, Thomas Klonisch, Sabine Hombach-Klonisch, Etienne Leygue, Sam Kung, Janice Safneck, Michael Mowat, Wayne Xu, Leigh Murphy, Marshall Pitz
BACKGROUND: Few descriptive epidemiological studies on the incidence, treatment and survival can accurately reflect a whole population. Manitoba, Canada has an accurate cancer registry, a drug information program network and a breast screening program since 1995. This combined with a stable population provides true population data that can accurately describe the region. METHODS: Using a retrospective cohort design all Breast Cancer cases were obtained from 2004-2010 (N=5399) and grouped by Intrinsic sub-type...
December 2016: Cancer Epidemiology
https://www.readbyqxmd.com/read/27766556/women-with-low-risk-dcis-eligible-for-the-loris-trial-after-complete-surgical-excision-how-low-is-their-risk-after-standard-therapy
#8
Melissa Pilewskie, Cristina Olcese, Sujata Patil, Kimberly J Van Zee
BACKGROUND: Identifying DCIS patients at low risk for disease progression could obviate need for standard therapy. The LORIS (surgery versus active monitoring for low-risk DCIS) trial is studying the safety of monitoring low-risk DCIS, although ipsilateral breast tumor recurrence (IBTR) rates in patients meeting enrollment criteria after complete surgical excision are unknown. METHODS: Women with pure DCIS treated with breast-conserving surgery (BCS) with/without radiation therapy (RT) from 1/1996-1/2011 were included from a prospectively maintained database...
October 20, 2016: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/27757718/outcomes-of-patients-with-inflammatory-breast-cancer-treated-by-breast-conserving-surgery
#9
Monika Brzezinska, Linda J Williams, Jeremy Thomas, J Michael Dixon
PURPOSE: Inflammatory breast cancer (IBC) is rare and associated with a poor prognosis. Following neoadjuvant chemotherapy or endocrine therapy, the multidisciplinary team selected a small number of patients for breast-conservation therapy (BCT). The aim of this study was to determine the outcome of IBC patients treated with BCT in Edinburgh. METHODS: Between January 1999 and December 2013, thirty-five women with IBC were treated by BCT. The median follow-up was 80 months...
October 18, 2016: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/27746881/gastric-metastasis-of-breast-cancer-a-case-series
#10
Gustavo Dos Santos Fernandes, Luiza D Batista Bugiato Faria, Isadora de Assis Pereira, Natália C Moreira Neves, Yasmine Oliveira Vieira, Alessandro I Cavalcanti Leal
Gastric metastasis is rare but it can be the initial symptom of cancer. The second leading cause of this type of metastasis is breast cancer. A lack of clinical signs and nonspecific side effects of the treatment of primary tumors can lead to the misdiagnosis of metastatic gastric cancer. Upper gastrointestinal endoscopy with biopsy and immunohistochemistry should be used for diagnosis. Treatment is palliative; it includes chemo, endocrine, and radiation therapies. Four patients with breast cancer and gastric metastasis were identified...
September 5, 2016: Rare Tumors
https://www.readbyqxmd.com/read/27721710/memory-and-spatial-cognition-in-breast-cancer-patients-undergoing-adjuvant-endocrine-therapy
#11
Ute Berndt, Bernd Leplow, Robby Schoenfeld, Tilmann Lantzsch, Regina Grosse, Christoph Thomssen
INTRODUCTION: It is generally accepted that estrogens play a protective role in cognitive function. Therefore, it can be expected that subtotal estrogen deprivation following aromatase inhibition will alter cognitive performance. METHODS: In a cross-sectional study we investigated 80 postmenopausal women with breast cancer. Memory and spatial cognition were compared across 4 treatment groups: tamoxifen only (TAM, n = 22), aromatase inhibitor only (AI, n = 22), TAM followed by AI ('SWITCH group', n = 15), and patients with local therapy (LT) only (surgery and radiation, n = 21)...
August 2016: Breast Care
https://www.readbyqxmd.com/read/27699555/adjuvant-radiation-use-in-older-women-with-early-stage-breast-cancer-at-johns-hopkins
#12
YaoYao G Pollock, Amanda L Blackford, Stacie C Jeter, Jean Wright, Ashley Cimino-Mathews, Melissa Camp, Susan Harvey, Fariba Asrari, Nancy L Schoenborn, Vered Stearns
PURPOSE: In 2004, The National Comprehensive Cancer Network (NCCN) Guidelines incorporated omission of radiation therapy after breast-conservation surgery in women ≥70 years old with stage I, estrogen receptor-positive breast cancer who plan to receive endocrine therapy. One study demonstrated wide variation in implementing this change across 13 NCCN institutions. We evaluated the practice pattern at our institution. METHODS: We identified women ≥70 years old treated at our institution from 2009 to 2014...
November 2016: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/27685357/comparison-of-treatment-outcomes-between-breast-conserving-surgery-followed-by-radiotherapy-and-mastectomy-alone-in-patients-with-t1-2-stage-and-1-3-axillary-lymph-nodes-in-the-era-of-modern-adjuvant-systemic-treatments
#13
Sang-Won Kim, Mison Chun, Sehwan Han, Yong Sik Jung, Jin Hyuk Choi, Seok Yun Kang, Hyunsoo Jang, Sunmi Jo
PURPOSE: The role of postmastectomy radiotherapy in the treatment of T1-2 primary tumor with 1-3 positive lymph nodes is controversial. We compared treatment outcomes between breast conserving surgery followed by radiotherapy (BCS+RT) and total mastectomy alone (TM) in the setting of modern adjuvant systemic treatments. METHODS: Patients with T1-2 primary breast cancer and 1-3 positive lymph nodes who were treated between 2001 and 2011 were divided into 2 groups based on the treatment approach: BCS+RT (n = 169) and TM (n = 117)...
2016: PloS One
https://www.readbyqxmd.com/read/27683343/molecular-classification-of-breast-cancer-tumours-from-patients-treated-with-doxorubicin-and-docetaxel
#14
Atocha Romero Alfonso
It is known that four main molecular breast cancer subtypes have different prognoses and different responses to therapy. Luminal A tumours have a better prognosis and they tend to be sensitive to anti-estrogen drugs. Luminal B tumours have incomplete sensitivity to endocrine therapy. Her2 tumours, which have an aggressive natural history, are sensitive to trastuzumab. Finally, basal-like tumours might be eligible for chemotherapy. The aim of this study was to evaluate the chemosensitivity to docetaxel and doxorubicin of breast cancer subtypes...
January 2010: EJIFCC
https://www.readbyqxmd.com/read/27671693/finding-the-balance-between-over-and-under-treatment-of-ductal-carcinoma-in-situ-dcis
#15
Emma J Groen, Lotte E Elshof, Lindy L Visser, Emiel J Th Rutgers, Hillegonda A O Winter-Warnars, Esther H Lips, Jelle Wesseling
With the widespread adoption of population-based breast cancer screening, ductal carcinoma in situ (DCIS) has come to represent 20-25% of all breast neoplastic lesions diagnosed. Current treatment aims at preventing invasive breast cancer, but the majority of DCIS lesions will never progress to invasive disease. Still, DCIS is treated by surgical excision, followed by radiotherapy as part of breast conserving treatment, and/or endocrine therapy. This implies over-treatment of the majority of DCIS, as less than 1% of DCIS patients will go on to develop invasive breast cancer annually...
September 23, 2016: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/27663568/trends-in-neoadjuvant-endocrine-therapy-use-and-impact-on-rates-of-breast-conservation-in-hormone-receptor-positive-breast-cancer-a-national-cancer-data-base-study
#16
Akiko Chiba, Tanya L Hoskin, Courtney N Heins, Kelly K Hunt, Elizabeth B Habermann, Judy C Boughey
BACKGROUND: The American College of Surgeons Oncology Group Z1031 trial demonstrated that neoadjuvant endocrine therapy (NET) increased breast-conserving surgery (BCS) rates for postmenopausal patients with clinical tumor stage 2-4c estrogen receptor-positive breast cancer. We evaluated national trends in NET use in relation to the conduct of the Z1031 trial and the impact of NET on the rates of BCS. METHODS: Using the National Cancer Data Base (NCDB), we identified all cT2-4c hormone receptor (HR)-positive breast cancer patients age ≥50 years from 2004 to 2012...
September 23, 2016: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/27652155/imatinib-could-be-a-new-strategy-for-pulmonary-hypertension-caused-by-pulmonary-tumor-thrombotic-microangiopathy-in-metastatic-breast-cancer
#17
Ippei Fukada, Kazuhiro Araki, Kokoro Kobayashi, Tomoko Shibayama, Masaru Hatano, Shunji Takahashi, Takuji Iwase, Shinji Ohno, Yoshinori Ito
INTRODUCTION: Pulmonary tumor thrombotic microangiopathy (PTTM) is rare, cancer-related pulmonary complication leading to hypoxia, pulmonary hypertension, and heart failure. The standard treatment for PTTM is not established. However, imatinib, a tyrosine kinase inhibitor of the PDGF receptor, may cause regression of pulmonary hypertension and pulmonary artery remodeling in PTTM. CASE DESCRIPTIONS: We report two cases of PTTM who received an anti-PDGF agent of imatinib for PTTM developed during chemotherapy for metastatic breast cancer...
2016: SpringerPlus
https://www.readbyqxmd.com/read/27635622/evaluating-candidacy-for-hypofractionated-radiation-therapy-accelerated-partial-breast-irradiation-and-endocrine-therapy-after-breast-conserving-surgery-a-surveillance-epidemiology-and-end-results-seer-analysis
#18
Bindu V Manyam, Rahul Tendulkar, Sheen Cherian, Frank Vicini, Shahed N Badiyan, Chirag Shah
PURPOSE/OBJECTIVE(S): After breast conserving surgery, adjuvant radiation therapy represents the standard of care for most patients. However, multiple options exist beyond standard fractionated whole breast irradiation including hypofractionated whole breast irradiation (HFRT), accelerated partial breast irradiation (APBI), and endocrine therapy (ET) alone, which can limit treatment duration, and potentially reduce morbidity and cost. Limited data are available on the percentage of patients eligible for these alternatives; therefore, a Surveillance Epidemiology and End Results (SEER) analysis was performed to assess candidacy for these alternative options in women with early stage breast cancer...
September 15, 2016: American Journal of Clinical Oncology
https://www.readbyqxmd.com/read/27633413/current-trends-in-the-management-of-ductal-carcinoma-in-situ
#19
REVIEW
Tristen S Park, E Shelley Hwang
Ductal carcinoma in situ (DCIS), once a rare entity, now comprises up to 30% of newly diagnosed breast cancers detected on mammography. It is now appreciated as a widely heterogeneous disease, with indolent lesions of minimal clinical significance on one end of the spectrum, and aggressive lesions with malignant invasive potential on the other. Therefore, the traditional guideline-concordant approach to treatment with surgery, radiation, and endocrine therapy may lead to overtreatment of certain patients, and insufficient treatment of others...
September 15, 2016: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/27628678/post-relapse-survival-in-patients-with-the-early-and-late-distant-recurrence-in-estrogen-receptor-positive-her2-negative-breast-cancer
#20
Akiko Ogiya, Kieko Yamazaki, Rie Horii, Tadahiko Shien, Yoshiya Horimoto, Norikazu Masuda, Touko Inao, Mitsuchika Hosoda, Naoko Ishida, Tomofumi Osako, Masato Takahashi, Yumi Endo, Yuichiro Miyoshi, Hiroyuki Yasojima, Nobumoto Tomioka, Hiroko Yamashita
BACKGROUND: Few studies have been performed on post-relapse survival in patients with the early and late distant recurrence in estrogen receptor (ER)-positive, HER2-negative breast cancer. METHODS: A total of 205 patients with the early distant recurrence and 134 patients with the late distant recurrence of ER-positive, HER2-negative breast cancer who had undergone breast surgery or neoadjuvant chemotherapy between January 2000 and December 2004 were registered from nine institutions...
September 15, 2016: Breast Cancer: the Journal of the Japanese Breast Cancer Society
keyword
keyword
121072
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"